ANN ARBOR, MI--(Marketwire - November 10, 2008) - Adeona Pharmaceuticals, Inc. (AMEX: AEN), a late-stage pharmaceutical company developing innovative drug candidates for the treatment of autoimmune and central nervous system diseases, announced the issuance of U.S. Patent No. 7,416,741 containing claims covering the use of thiomolybdates such as oral tiomolibdate diammonium (USAN name for oral tetrathiomolybdate, or TTM) for the treatment of Alzheimer’s disease (AD).
